Stories about Multiple sclerosis
Merck to Showcase New Data Across MS Portfolio at EAN 2019
Merck Pioneers New Efforts to See MS From the Inside Out
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt
Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis
Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Euthyrox®
1